The state of Maryland currently has 35 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Spironolactone for Pulmonary Arterial Hypertension
Recruiting
Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to worsening of the disease. A drug called spironolactone has been known to improve blood vessel function and reduce inflammation. Some people with PAH take spironolactone to help treat fluid retention.... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Arterial Hypertension
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/11/2025
Locations: Research Site, Bethesda, Maryland +1 locations
Conditions: Chronic Kidney Disease and Hypertension
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
Recruiting
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Site 440, Rockville, Maryland
Conditions: Resistant Hypertension, Hypercortisolism
Diabetes and Heart Disease Risk in Blacks
Recruiting
It is unknown if obesity contributes to the development of heart disease in African American men and women. This study was created to determine whether there is a relationship between sex and body size and the incidence of heart disease in African American men and women. Researchers will attempt to associate obesity with the presence of heart disease risk factors. Risk factors that will be studied include; total body fat, body fat distribution, fat content of the blood (triglyceride concentrati... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Diabetes, Obesity, Hypertension, Cardiovascular Diseases
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Recruiting
Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH. Objectives: - To study the natur... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Disease, Pulmonary Hypertension
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2025
Locations: Ascension Saint Agnes Heart Care, Baltimore, Maryland +2 locations
Conditions: Hypertension
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting
Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited. Objective: To study the genes that may cause primary aldosteronism in Black individuals. Eligibility: People ages 18-70 who: Are Black, African American, or of Caribbean descent And have difficult to control blood pressu... Read More
Gender:
ALL
Ages:
Between 7 years and 70 years
Trial Updated:
07/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Natural History of Noncirrhotic Portal Hypertension
Recruiting
Background: - Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH. Objectives: - To learn more about how NCPH develops over time. Eligibility: - People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other... Read More
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: The Johns Hopkins University, Baltimore, Maryland
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland +1 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Recruiting
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pulmonary Arterial Hypertension
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Bethesda, Maryland
Conditions: Chronic Kidney Disease and Hypertension